{"id":"arina-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARINA-1 works by correcting the folding and stability of the CFTR protein, allowing it to reach the cell surface and function properly. This leads to improved chloride ion transport across epithelial cell membranes, which helps to thin mucus and improve lung function in patients with cystic fibrosis.","oneSentence":"ARINA-1 is a small molecule inhaled cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:15.189Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT05654922","phase":"PHASE3","title":"Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant","status":"RECRUITING","sponsor":"Renovion, Inc.","startDate":"2023-04-10","conditions":"Pre-Bronchiolitis Obliterans Syndrome","enrollment":100},{"nctId":"NCT05495243","phase":"PHASE2","title":"Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough","status":"COMPLETED","sponsor":"Renovion, Inc.","startDate":"2022-10-03","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":40},{"nctId":"NCT05658029","phase":"PHASE1","title":"An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy","status":"WITHDRAWN","sponsor":"Matthew Bruehl","startDate":"2023-05-23","conditions":"Tracheostomy","enrollment":""},{"nctId":"NCT03226431","phase":"PHASE1","title":"Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-12-11","conditions":"Lung Transplant","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ARINA-1","genericName":"ARINA-1","companyName":"Renovion, Inc.","companyId":"renovion-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARINA-1 is a small molecule inhaled cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}